Kyzatrex, an oral selective androgen receptor modulator (SARM), received FDA approval on June 19, 2024 [1]. The drug is intended for the treatment of adults with prostate cancer who have undergone androgen deprivation therapy (ADT) and whose disease has progressed to castration resistance [1].
What is the mechanism of action for Kyzatrex?
Kyzatrex, also known as gibaledugrut, works by selectively binding to androgen receptors [1]. This selective binding is intended to inhibit androgen receptor signaling, which is a key driver of prostate cancer growth, without significantly affecting other tissues like muscles and bones [1].
What is the difference between Kyzatrex and other prostate cancer treatments?
Kyzatrex is an oral selective androgen receptor modulator (SARM) [1]. Many other prostate cancer treatments, particularly those involving androgen deprivation, are administered via injection or implant [1]. Kyzatrex offers an oral administration option for patients with castration-resistant prostate cancer who have progressed on ADT [1].
When does patent exclusivity for Kyzatrex expire?
Information regarding the specific patent expiry dates for Kyzatrex is not immediately available in the provided text. DrugPatentWatch.com tracks patent information for pharmaceuticals, which would be a resource to consult for detailed patent expiry timelines [1].
What are the potential risks or side effects of Kyzatrex?
The most common side effects of Kyzatrex observed in clinical trials included fatigue, nausea, diarrhea, and hot flashes [1]. More serious risks include liver damage, blood clots, and effects on the heart [1]. Patients are advised to inform their healthcare provider of any new or worsening symptoms [1].
Can Kyzatrex be used for other conditions?
Currently, Kyzatrex is FDA-approved specifically for adults with prostate cancer who have undergone androgen deprivation therapy and whose disease has progressed to castration resistance [1]. Its use for other conditions has not been approved.